Publications by authors named "H Kagamu"
Objectives: Programmed cell death ligand 1 (PD-L1) expression is widely used to predict the effectiveness of PD-(L)1 inhibitors despite its imperfection. Previous studies suggested the utilization of various serum biomarkers; nonetheless, findings are inconclusive because of limited sample sizes or the focus on a single biomarker in many of these studies. This study analyzed multiplex serum biomarkers to explore their predictive ability in a large cohort of patients with advanced non-small-cell lung cancer (NSCLC) treated with a PD-L1 inhibitor in a real-world setting.
View Article and Find Full Text PDFArticle Synopsis
- This study looked at how cardiac uptake of F-FDG PET, a commonly used imaging technique for cancer, relates to cancer cachexia and overall survival in patients with advanced non-small cell lung cancer (NSCLC).
- Researchers evaluated 43 patients who experienced weight loss before starting treatment and found that low visual scores for cardiac F-FDG uptake correlated with higher tumor activity and a higher risk of cachexia.
- The findings suggest that lower cardiac F-FDG uptake indicates poorer nutritional status and is a significant predictor of reduced overall survival for patients with advanced NSCLC.
Article Synopsis
- The study investigates the effectiveness of durvalumab, an immunotherapy drug, after chemoradiotherapy in patients with unresectable locally advanced non-small-cell lung cancer (LA-NSCLC), particularly those with poorer performance status or older age.
- In a phase II trial with 86 participants, 61 received durvalumab after low-dose carboplatin and radiotherapy, showing a 12-month progression-free survival (PFS) rate of 51%, exceeding the expected 35%.
- The treatment was deemed effective, with a median overall survival of 28.1 months, but pneumonitis was noted as the most common severe side effect.*
Background: The L-type amino acid transporter (LAT1) exhibits significantly increased expression within tumor cells across various neoplasms. However, the clinical significance of LAT1 expression in patients with pleural mesothelioma (PM) remains unclear.
Methods: Eighty patients diagnosed with PM between June 2007 and August 2022, were eligible for this study.
Background: The standard treatment for patients in good general condition with limited-disease small cell lung cancer (LD-SCLC) is concurrent platinum/etoposide chemotherapy and thoracic radiotherapy (TRT). However, the efficacy and safety of chemoradiotherapy (CRT) in older patients with LD-SCLC has not been fully explored; moreover, the optimal treatment for this patient group remains unclear. This study aimed to investigate the feasibility and efficacy of CRT in older patients with LD-SCLC.
View Article and Find Full Text PDF